Flagship · Bulletin

Macro rationale

Live inputs are benign — VIX 15.19 (−17.96% vs 200d), HY OAS 2.67, 2s10s +0.38 positively sloped — but the macro digest's QQQ +10.54% extension signal is ACTIVE, which is the named citation permitting cash above the NEUTRAL base ceiling of 15%. Underneath the placid tape the flow picture is unchanged from the prior five runs: first negative payroll of the cycle (−23k July, −103k revisions), Fed pinned at 3.63% with three hawkish dissents wanting a HIKE, 10y at 4.68% with a 2.43% real yield, and HY OAS inside its richest historical decile. That is a stagflationary vise with no Fed put, which sustains NEUTRAL with a defensive tilt — energy/defense OW, biology UW, compute neutral with a physical-infrastructure tilt. Gold at $4,429 and softening Sep hike odds (~33%) are noted but neither shifts the regime. Critically for this event-driven run: not one named FUNDER moved. Hyperscaler capex (~$600B AMZN/GOOGL/MSFT, ~$725B top-five 2026), HBM sold out across the three-player oligopoly through 2026, copper at all-time highs with AI datacenters at ~50k tonnes/facility, the $1.5T FY2027 defense request, and the GLP-1/FcRn commercial franchises are all intact. The week's price events (ARGX +11.13%, AVGO −5.81%, LUNR's post-SpaceX-IPO derating) are tape and sentiment, not capital-flow reversals. Cash is carried at the top of the escalated band, cited on extension, per §5.4.

Thesis

Scope-locked event run over [ARGX, AVGO, LUNR, MU, TSM, NVDA, ASML, ANET, LLY, VRTX]; everything else is held verbatim at prior entry weight, delta 0. One real ticket: CLOSE LUNR. The positionBriefer verdict is broken at score 54 — below the 60 floor — with unlock path B active, and the two high-tier haiku flags corroborate rather than contradict: the Aug-18 NITE-STAR award spread $981M across 15 firms (~$6.5M/yr each), which is not a needle-mover against a −70% post-SpaceX-IPO derating and 28.85% short interest. My own ledger records the PSN lesson twice: carrying a name I have judged broken because a position-count technicality blocks the close is asymmetrically expensive. LUNR is 1.26% of NAV and is the book's only broken verdict — take it out. On the other three trigger names, nothing that touches a funder. ARGX +11.13% is CONFIRMATORY, not a reason to trim: Sanofi's riliprubart CIDP failure removes the one credible near-term challenger to Vyvgart in CIDP, and the $77/share Forte tender (closing ~Aug 26) extends the platform beyond FcRn to anti-CD122. Trimming a compounder on the day its competitive moat widened is exactly the churn this book exists to avoid — hold at 3.79%. MU's high flag is Druckenmiller selling 23.4k shares after the stock tripled; that is profit-taking, not the 16-SCA ~$100B contract book breaking. Score 87, drift +10, hold. AVGO score 63 is de-rating on a BofA note about a $370B modeled financing ceiling — a narrative, not a debt balance; the ASIC f

Reflection

Four price triggers, zero funder breaks — ARGX +11% is Sanofi's CIDP failure widening the moat. Only real ticket is closing LUNR on a broken verdict.

I finally acted on the PSN lesson instead of restating it: LUNR was judged broken and I closed it rather than carry a 1.26% sliver on a position-count technicality. The tension I flagged last week resolved the wrong way and the right way at once — a THIRD compute name did not join AVGO/ASML in the low-60s (NVDA drifted to 74 but held), so my drift-is-not-a-trigger stance survives another week. What genuinely surprises me: ARGX's +11% came from a COMPETITOR failing, which is the cleanest kind of moat news and the opposite of a reason to trim on drift, yet the briefer's instinct was to trim it b

Positions (14)

• MUMicron Technologycompute

  hold3.69%87
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise: 84.6% gross margin, FCF positive, and genuine supply discipline after two decades of cycle abuse — the three-player HBM oligopoly (SK Hynix/Micron/Samsung) has 2026 output fully sold out, which is a structurally different memory market than any prior cycle. Named flow: 16 multi-year Strategic Customer Agreements worth ~$100B contracted, the Anthro

  Unwind

  Erosion of the 16-SCA contract book; HBM oversupply as new capacity lands late-2026; a hyperscaler capex cut; or CXMT Beijing capacity landing at scale in commodity DRAM and breaking pricing discipline.

  Catalyst

  FQ4 results and the HBM4 qualification cadence; next SCA disclosure confirming the contracted book.

  Scenarios · 12mo targets

  $360.00 base

  $460.00 bull — HBM4 qualifies across NVDA/AMD platforms, 2027 capacity stays contracted, and memory holds oligopoly pricing through the next node transition.

  $230.00 bear — Late-2026 HBM capacity lands into a hyperscaler capex digestion pause and CXMT floods commodity DRAM, collapsing the pricing premium.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.58%86
  flow acceleratingconf

  Funder

  World-leading foundry with an effective monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry and ~90% advanced-node share, and a management culture that has compounded through four decades of cycles. Named flow: Amazon, Alphabet and Microsoft collectively deploying ~$600B of datacenter capex with TSMC ide

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or forward P/E breaching 35x.

  Catalyst

  Monthly revenue prints and the next capex guide; CoWoS capacity milestone at 130k WPM by Q4 2026.

  Scenarios · 12mo targets

  $380.00 base

  $460.00 bull — 2nm ramps on schedule with pricing power intact and 2027 AI capex guides toward the $920B-$1.4T range Goldman models, with TSMC named explicitly.

  $260.00 bear — A Taiwan-strait escalation or an AI capex digestion year forces a capex cut and multiple compression from 31x forward.

• NVDANVIDIAcompute

  hold3.45%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — ~74.9% gross margin, fortress balance sheet, developer lock-in no ASIC rival has replicated in a decade. Named flow: ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B), the Stargate $500B JV, the HIVE $350M Blackwell order, and SpaceX's $15.8B AI capex commitment. Score drift to

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; hyperscaler in-sourcing plus AMD wins pushing competitor share toward the 25% TAM invalidation line; or a compute export-control regime removing a material revenue block.

  Catalyst

  Aug 26 earnings — the named near-term test of the 96% YoY sales-growth expectation.

  Scenarios · 12mo targets

  $250.00 base

  $310.00 bull — Rubin pulls forward, inference share holds above 70%, and the 2027 hyperscaler capex line steps up again rather than digesting.

  $165.00 bear — Post-earnings multiple compression on the historical 2-5% drawdown pattern compounds with Meta/Google custom-silicon share gains taking accelerator TAM share.

• ASMLASML Holdingcompute

  hold2.83%61
  flow softeningconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, no commercial-scale alternative at 2nm, multi-year backlog, ~50% gross margin and an installed-base service annuity that survives order troughs. Named flow: Intel's July 2026 Ultra 3 High-NA design win confirming volume deployment; the TSMC/Samsung/Intel 2025-27 EUV orderbook; Norway GPFG holds, Coatue and Third Point a

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; or a credible non-EUV patterning path at 2nm.

  Catalyst

  Next quarterly book-to-bill print — the named threshold is 0.7; and China revenue floor confirmation.

  Scenarios · 12mo targets

  $1,350.00 base

  $1,650.00 bull — High-NA moves from single tools to fleet orders across TSMC/Intel/Samsung and the service annuity re-rates the backlog visibility.

  $950.00 bear — Chinese domestic DUV takes the remaining 16% China revenue and a leading-edge capex pause pushes book-to-bill below 0.7 for three quarters.

• AVGOBroadcomcompute

  hold2.79%63
  flow softeningconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software lock-in — 69.5% gross margin, huge FCF, $7B+ annual buyback, serial dividend grower, and one of the best capital-allocation records in semis under Tan. Named flow: Google TPU multi-generation, Meta MTIA, and the Anthropic 3.5GW ASIC program; Q2 AI segment +143% to $10.8B with $30B+ bookings. The BofA downgrade concerns

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise; VMware renewal churn breaking the software annuity; or actual drawn leverage on the AI financing platform impairing the buyback.

  Catalyst

  Next quarterly AI-segment revenue print and any disclosure quantifying real drawn debt on the AI financing platform.

  Scenarios · 12mo targets

  $450.00 base

  $560.00 bull — A fourth named hyperscaler ASIC program lands and VMware renewal pricing holds, taking AI revenue past a $40B run-rate.

  $300.00 bear — The AI financing platform converts to real leverage, forcing buyback suspension while a hyperscaler pulls an ASIC program in-house.

• ANETArista Networkscompute

  hold2.49%65
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, net cash, no debt, and the single-image EOS software moat that keeps switching costs high; Ullal-led capital discipline. Named flow: Microsoft and Meta named as its two largest customers funding the first $3B quarter (Q2 revenue $3.036B, +37.7% YoY) and an FY guide raised to $12.6B (~40% growth)

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; or gross margin breaking below 60%.

  Catalyst

  Next quarterly print and any disclosed Spectrum-X displacement at a named hyperscaler.

  Scenarios · 12mo targets

  $200.00 base

  $250.00 bull — Ethernet keeps winning the AI back-end against InfiniBand, the net-new hyperscaler scales, and FY2027 guides above 30% again.

  $130.00 bear — Nvidia Spectrum-X (already $14.8B, +199% YoY) takes a named Microsoft or Meta cluster and the 42% customer concentration turns into a revenue cliff.

• GEVGE Vernovaenergy

  hold4.92%61
  flow steadyconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — record ~$176B backlog running through 2031, heavy-duty turbines effectively sold out through 2030, 10-20% price realization on new orders, quadrupled FCF, and a three-player global oligopoly in heavy-duty turbines. Named flow: Norway GPFG added post-spin; Oracle and Alphabet datacenter capex pull-through; the DOE Gen III+ SMR Tier 1 $800M

  Unwind

  Gas-turbine backlog cancellation or a hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or EV/EBITDA breaching the 25x invalidation ceiling.

  Catalyst

  Next backlog/orders disclosure and the Clinch River BWRX-300 licensing milestone.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,400.00 bull — Backlog converts on schedule, wind losses are ring-fenced, and SMR moves from award to firm order book, adding a second multi-decade leg.

  $750.00 bear — A datacenter power-capex pause plus widening wind losses de-rates a 34x 2026 earnings multiple after a 674% run.

• SCCOSouthern Copperenergy

  hold8.30%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive and a large dividend; Grupo Mexico control enforces capital discipline through the cycle. Named flow: copper at all-time highs above $6.50/lb on a ~320k-tonne 2026 deficit, BHP's earnings showing copper now out-earning iron ore, and AI datacenters consuming ~50k

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican expropriation or royalty shock.

  Catalyst

  Tia Maria / Los Chancas permitting decision; next quarterly copper realization and dividend declaration.

  Scenarios · 12mo targets

  $165.00 base

  $200.00 bull — The structural deficit widens as grid and datacenter demand compounds while no major new supply lands, and Tia Maria permits clear.

  $115.00 bear — A global demand shock from the cracking labor market collapses copper, and Peruvian permitting or royalty politics re-rate the asset base.

• NEMNewmont Corporationenergy

  hold5.47%84
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: gold at $4,429 on sustained central-bank accumulation and reserve diversification away from USD; TD Cowen upgrade to Buy on valuation; the structural hedge against a Fed pinned at 3.63% with hawkis

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or a persistent miner-vs-physical underperformance spread signalling the equity is not transmitting the gold bid.

  Catalyst

  Jackson Hole (Aug 27-29) and the Sep 15-16 FOMC — the reaction-function reads that drive real yields and the gold bid.

  Scenarios · 12mo targets

  $120.00 base

  $150.00 bull — The Fed is forced to ease into above-target inflation, real yields fall, and central-bank buying keeps gold bid while Newmont's cost curve keeps improving.

  $85.00 bear — Core CPI breaks below 2.2% for two prints, real yields surge, gold de-rates, and the miner-vs-physical spread widens further against GDX.

• KTOSKratos Defensedefense

  hold8.92%64
  flow steadyconf

  Funder

  Tactical drones (XQ-58A Valkyrie), hypersonics and turbine engines — a scarce non-prime supplier of attritable airframes with a decade of embedded program positions the primes cannot easily displace. Named flow: DoD MACH-TB 2.0 $1.45B IDIQ ceiling (prime), Project Helios $68.3M single-award hypersonic materials center, USMC XQ-58A MUX TACAIR mods, a $49M NSWC Oriole solid-rocket-motor contract, an

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut; or an FY2027 appropriation that strips the drone-dominance line.

  Catalyst

  FY2027 appropriations / the continuing-resolution deadline (currently Dec 4) governing new-start obligation flow.

  Scenarios · 12mo targets

  $85.00 base

  $110.00 bull — Valkyrie moves from mods to a production-rate program of record and the SRM/Oriole line scales into the funded munitions-industrial-base expansion.

  $50.00 bear — A long CR strands new starts, the drone ramp fails to inflect margin, and FCF stays negative through another fiscal year.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF at 20%+ with a disciplined serial-acquisition model (~$1B/yr) and PMA parts economics that are structurally sticky with airlines and MRO shops. Named flow: Q2 record net sales +25% and record net income +49% YoY (FSG $929M vs $864M consensus, ETG $460M vs

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the serial-acquirer discipline; or forward P/E sustained above the 54x invalidation threshold while growth decelerates.

  Catalyst

  Next quarterly FSG/ETG organic-growth split and the pace of tuck-in acquisitions.

  Scenarios · 12mo targets

  $380.00 base

  $460.00 bull — Aftermarket demand stays structurally tight, tuck-ins keep compounding at historic returns, and FSG organic growth holds double digits.

  $270.00 bear — Air-traffic softening from the cracking consumer decelerates organic growth below 6% while a 54x forward multiple compresses.

• LLYEli Lillybiology

  hold3.60%74
  flow acceleratingconf

  Funder

  Premier pharma compounder — the Mounjaro/Zepbound tirzepatide franchise (~60% US share; Q2 Mounjaro $9.9B, Zepbound $4.9B) plus oral orforglipron and retatrutide in Phase 3, on 85.8% gross margin with a century-long capital-allocation record and $27B of manufacturing expansion funding the moat. Named flow: Foundayo won the UK's first oral GLP-1 approval — with no food restrictions, a competitive e

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; or IRA/MFP negotiation reaching the tirzepatide franchise and breaking price realization.

  Catalyst

  Retatrutide Phase 3 readouts and the US orforglipron launch cadence; any CMS coverage-policy update on obesity drugs.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,500.00 bull — Retatrutide confirms best-in-class weight loss, orforglipron scales the oral market Lilly already leads, and manufacturing capacity converts backlog demand to revenue.

  $880.00 bear — A retatrutide safety signal plus IRA price negotiation reaching tirzepatide compresses both the growth rate and the multiple.

• VRTXVertex Pharmaceuticalsbiology

  hold2.99%82
  flow acceleratingconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine with 85.3% gross margin, no meaningful competition and a fortress net-cash balance sheet — a rare biotech insulated from the rate vise because it does not need capital markets. Named flow: the $10B Crinetics acquisition extends the franchise into endocrinology and the anti-obesity adjacency,

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value or pushing forward P/E toward the 30x invalidation line; or a suzetrigine launch that fails to gain formulary traction.

  Catalyst

  Crinetics deal close and integration disclosure; suzetrigine launch-traction metrics.

  Scenarios · 12mo targets

  $540.00 base

  $650.00 bull — Suzetrigine converts a meaningful share of the non-opioid pain market and Crinetics gives a genuine second growth engine beyond CF.

  $390.00 bear — Crinetics proves a $10B overpay, suzetrigine formulary uptake stalls, and CF growth flattens with nothing to replace it.

• ARGXargenxbiology

  hold2.94%70
  flow acceleratingconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, self-funded, commercial-stage, high-margin and net cash, so it does not depend on capital markets in a 4.68% 10y world. Named flow this week is a widening moat, not a price event: Sanofi's riliprubart FAILED in CIDP, removing the most credible near-term challenger

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share; or the Forte deal turning into a value-destroying integration.

  Catalyst

  Forte tender close ~Aug 26; myositis and Sjogren's label-expansion filings and EU reimbursement decisions.

  Scenarios · 12mo targets

  $960.00 base

  $1,150.00 bull — CIDP becomes an uncontested Vyvgart market after the Sanofi failure and myositis/Sjogren's labels convert the platform into a multi-indication annuity.

  $680.00 bear — A pipeline indication misses, a rival FcRn entrant takes measurable share, and the Forte acquisition dilutes focus without adding revenue.

Warnings

• stale_policy guard: KLAC open → hold (delta zeroed)
• stale_policy guard: GD open → hold (delta zeroed)
• stale_policy guard: VEEV open → hold (delta zeroed)
• stale_policy guard: ILMN open → hold (delta zeroed)
• §2 cap re-applied after pillar tilt: HEI
• §5.4 dry-powder: cash_pct 16.09% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)
• cash_band: final cash 31.8% above neutral base band top 15% (escalator active: extension; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)
• position_count: 14 < 16 after mechanical closes (§2 floor) — book under-populated; strategist must open replacements next run
• buy guard dropped 1 open(s): ILMN (§3/§4/§6.3)

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —
3. Turn 3ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.